Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RAPT
stocks logo

RAPT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.762
-92.19%
--
--
-0.733
+14.58%
--
--
-0.827
+27.18%
Estimates Revision
The market is revising No Change the revenue expectations for RAPT Therapeutics, Inc. (RAPT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 166.59%.
EPS Estimates for FY2025
Revise Upward
up Image
+34.8%
In Past 3 Month
Stock Price
Go Up
up Image
+166.59%
In Past 3 Month
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 64.38 USD with a low forecast of 56.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 64.38 USD with a low forecast of 56.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.470
sliders
Low
56.00
Averages
64.38
High
72.00
Current: 34.470
sliders
Low
56.00
Averages
64.38
High
72.00
JPMorgan
NULL -> Overweight
maintain
$55 -> $57
2025-11-12
Reason
JPMorgan
Price Target
$55 -> $57
2025-11-12
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Rapt Therapeutics to $57 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Barclays
Overweight
downgrade
$58 -> $56
2025-11-07
Reason
Barclays
Price Target
$58 -> $56
2025-11-07
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Rapt Therapeutics to $56 from $58 and keeps an Overweight rating on the shares following the Q3 report.
Clear Street
Buy
maintain
$60
2025-11-06
Reason
Clear Street
Price Target
$60
2025-11-06
maintain
Buy
Reason
Clear Street views the shares of Rapt Therapeutics as "exceptionally compelling" following the company's Q3 report. The company achieved a "major milestone with compelling" Phase 2 chronic spontaneous urticaria data from its Chinese partner, Shanghai Jeyou Pharmaceutical, the analyst tells investors in a research note. The firm believes ozureprubart "stands out" with quarterly dosing, which is triple the convenience compared to Xolair's monthly regimen. Clear says Rapt shares are little changed spite this "significant de-risking event" and its financing overhang being eliminated. The firm keeps a Buy rating on shares with a $60 price target.
Wells Fargo
Overweight
maintain
$48 -> $72
2025-11-03
Reason
Wells Fargo
Price Target
$48 -> $72
2025-11-03
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Rapt Therapeutics to $72 from $48 and keeps an Overweight rating on the shares. Following its key opinion leader webinar and channel check on RPT904 CSU data and opportunity in food allergy and chronic spontaneous urticaria, the firm highlights its experts' positive view on RPT904's differentiation and future adoption even with the advent of Xolair biosimilars.
H.C. Wainwright
NULL -> Buy
upgrade
$27 -> $72
2025-10-27
Reason
H.C. Wainwright
Price Target
$27 -> $72
2025-10-27
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Rapt Therapeutics to $72 from $27 and keeps a Buy rating on the shares. The firm believes the positive data presented in chronic spontaneous urticaria "further de-risk" RPT904's clinical development. A single dose of RPT904 could potentially improve complete responses versus omalizumab, the analyst tells investors in a research note. H.C. Wainwright sees readthrough from the CSU data to Rapt's food allergy trial initiated today. It increased the probability of success in CSU and food allergy to 45% from 30%.
Guggenheim
Yatin Suneja
initiated
$70
2025-10-27
Reason
Guggenheim
Yatin Suneja
Price Target
$70
2025-10-27
initiated
Reason
Guggenheim analyst Yatin Suneja initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $70 price target based on a positive view of its longer-acting anti-IgE monoclonal antibody and its potential to capitalize on a rapidly growing food allergy market. The highly successful launch of Roche's (RHHBY) Xolair in food allergies has "caught many investors by surprise," says the analyst, who notes that Rapt's lead asset, RPT-904, is a longer-acting anti-IgE mAb with YTE mutation that has demonstrated about three times the half-life of Xolair.
See All Ratings

Valuation Metrics

The current forward P/E ratio for RAPT Therapeutics Inc (RAPT.O) is -10.79, compared to its 5-year average forward P/E of -6.05. For a more detailed relative valuation and DCF analysis to assess RAPT Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.05
Current PE
-10.79
Overvalued PE
-2.78
Undervalued PE
-9.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.43
Undervalued EV/EBITDA
-7.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
417.07
Current PS
0.00
Overvalued PS
1464.98
Undervalued PS
-630.84
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 392% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

RAPT News & Events

Events Timeline

(ET)
2025-11-06
08:04:31
Rapt Therapeutics announces Q3 earnings per share of 65 cents, falling short of the expected 85 cents.
select
2025-10-27 (ET)
2025-10-27
09:30:06
Clear Street optimistic about Rapt Therapeutics ahead of food allergy research.
select
2025-10-27
08:05:26
Rapt Therapeutics Launches Phase 2b Trial for prestIgE
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-14Yahoo Finance
Recent Developments Influencing the Randoncorp Investment Narrative

  • Fair Value and Analyst Sentiment: Randoncorp's fair value estimate remains at R$9.23 per share, with analysts expressing optimism due to clinical advancements and increased price targets from firms like JPMorgan and Barclays, despite some concerns about valuation and risks.

  • Clinical Progress and Market Potential: Strong clinical data for RPT904 in chronic spontaneous urticaria and food allergies has led to significant upgrades in price targets, with analysts highlighting its potential advantages over existing treatments.

  • Market Performance and Index Inclusion: Randoncorp's stock surged 27% following positive Phase 2 data and its recent addition to the Brazil IBRX Index, indicating a growing market relevance and investor confidence.

  • Ongoing Monitoring of Risks: While the overall sentiment is bullish, analysts are cautious about near-term risks related to upcoming data releases and the competitive landscape, emphasizing the need for risk management as the company progresses.

[object Object]
Preview
6.0
11-07Benzinga
Barclays Keeps Overweight Rating on RAPT Therapeutics, Reduces Price Target to $56

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve their trading outcomes.

  • Market Winning Tools: The platform is designed to equip traders with the tools they need to succeed in the stock market every day.

[object Object]
Preview
4.0
10-26Yahoo Finance
Wells Fargo Raises Price Target for RAPT Therapeutics (RAPT) to $48 Following Positive Anti-IgE Drug Results

  • RAPT Therapeutics Stock Potential: RAPT Therapeutics Inc. has been identified as a promising investment, with Wells Fargo raising its price target from $38 to $48 and maintaining an Overweight rating, based on positive data from a CSU study indicating strong drug efficacy.

  • Comparison with XOLAIR: The company's anti-IgE antibody therapy, RPT904, shows comparable or superior efficacy to XOLAIR, which treats various allergic conditions, suggesting a significant market opportunity for RAPT's drug in food allergies.

  • Company Overview: RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for oncology and inflammatory diseases, addressing unmet medical needs in the U.S.

  • Investment Considerations: While RAPT is seen as a valuable investment, there are suggestions that certain AI stocks may offer better upside potential and lower risk, prompting a recommendation to explore undervalued AI stocks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is RAPT Therapeutics Inc (RAPT) stock price today?

The current price of RAPT is 34.47 USD — it has increased 7.42 % in the last trading day.

arrow icon

What is RAPT Therapeutics Inc (RAPT)'s business?

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

arrow icon

What is the price predicton of RAPT Stock?

Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 64.38 USD with a low forecast of 56.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is RAPT Therapeutics Inc (RAPT)'s revenue for the last quarter?

RAPT Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is RAPT Therapeutics Inc (RAPT)'s earnings per share (EPS) for the last quarter?

RAPT Therapeutics Inc. EPS for the last quarter amounts to -0.65 USD, decreased -82.85 % YoY.

arrow icon

What changes have occurred in the market's expectations for RAPT Therapeutics Inc (RAPT)'s fundamentals?

The market is revising No Change the revenue expectations for RAPT Therapeutics, Inc. (RAPT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 166.59%.
arrow icon

How many employees does RAPT Therapeutics Inc (RAPT). have?

RAPT Therapeutics Inc (RAPT) has 68 emplpoyees as of December 05 2025.

arrow icon

What is RAPT Therapeutics Inc (RAPT) market cap?

Today RAPT has the market capitalization of 955.19M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free